Clinical Trial: CAR-T for Claudin18.2 Positive Solid Tumors

U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07266311) titled 'CAR-T for Claudin18.2 Positive Solid Tumors' on Nov. 22.

Brief Summary: The purpose of this clinical trial is to learn if autologous claudin18.2-directed chimeric antigen receptor T-cell (CAR-T) therapy works to treat claudin18.2 positive solid tumors in adults. It will also learn about the safety and efficacy of the autologous claudin18.2 CAR-T cell product.

The main questions it aims to answer are:

1. What CAR-T-related adverse events (AEs) occur within 3 months after the autologous CAR-T cell infusion?

2. What is the Objective Response Rate (ORR), Progression-free survival (PFS), duration of response (DOR), and overall survival...